Epimedium for Primary Osteoporosis: A Meta-Analysis of 890 Cases on BMD Improvement and Safety Profile

Primary osteoporosis (POP) is a global public health issue characterized by reduced bone mineral density (BMD), deterioration of bone tissue microarchitecture, and increased fracture risk. As the global population ages, the prevalence of primary osteoporosis continues to rise, placing significant burdens on healthcare systems and quality of life. Conventional pharmacotherapies, including bisphosphonates, denosumab, and selective estrogen receptor modulators, have demonstrated efficacy but raise long-term safety concerns such as atypical femoral fractures and osteonecrosis of the jaw.

This clinical challenge has driven renewed interest in plant-based therapeutic alternatives. Among these, Epimedium extract powder-derived from the leaves of Epimedium brevicornum Maxim.-has emerged as one of the most evidence-backed herbal interventions for bone health. In traditional Chinese medicine, Epimedium has been used for centuries to "tonify the kidneys and strengthen bones," with the Compendium of Materia Medica documenting its benefits for "nourishing essence and qi, strengthening tendons and bones, and tonifying the waist and knees." Modern pharmacological research has identified icariin and other flavonoids as the primary bioactive compounds responsible for its osteoprotective effects.

This article reviews the clinical evidence from a recent meta-analysis of 10 randomized controlled trials (RCTs) involving 890 patients, demonstrating that Epimedium extract significantly improves BMD, relieves lower back pain, and exhibits a favorable safety profile-positioning it as a promising natural alternative for primary osteoporosis management.

The Kidney-Bone Axis in Traditional Medicine

Traditional Chinese medicine theory holds that "the kidneys govern bones," and kidney essence deficiency is considered the core pathogenesis of osteoporosis. Epimedium, known as "Yinyanghuo" in Chinese medicine, has been valued for its ability to "tonify kidney yang" and "strengthen the skeletal system." This theoretical framework finds remarkable resonance with modern pharmacological discoveries.

Molecular Mechanisms of Icariin and Epimedium Flavonoids

Modern research has elucidated multiple mechanisms by which icariin-the principal active component of Epimedium extract powder-exerts its anti-osteoporotic effects. The therapeutic action operates through a sophisticated network of signaling pathways that simultaneously promote bone formation and inhibit bone resorption.

 PI3K/Akt/GSK3β/β‑Catenin Integrated Signaling Pathway

One of the most well-characterized mechanisms involves the PI3K/Akt/GSK3β/β‑catenin pathway. Studies demonstrate that icariin protects against glucocorticoid-induced osteoporosis by modulating this integrated signaling cascade. Dexamethasone (a glucocorticoid) suppresses the expression of DEC1, a structurally distinct helix-loop-helix protein, while icariin induces its expression. DEC1 overexpression promotes osteogenic activity, whereas DEC1 knockdown decreases it. Furthermore, DEC1 regulates the expression of β-catenin and PIK3CA-essential players in the Wnt/β-catenin and PI3K/Akt signaling pathways, respectively. Notably, inhibitors of these pathways (DKK1 for Wnt/β-catenin and LY294002 for PI3K/Akt) abolish the induction of DEC1 by icariin, confirming the interconnected nature of these pathways through the phosphorylation status of GSK3β. Dexamethasone decreases GSK3β phosphorylation while icariin increases it, tipping the balance toward bone formation .

HIF‑1α as a Novel Therapeutic Target

Recent network pharmacology analysis has identified 65 potential active compounds, 258 potential target proteins, and 488 pathways of Epimedium, revealing a far more complex picture than previously understood . Among these, hypoxia-inducible factor‑1α (HIF‑1α) has emerged as a critical therapeutic target. In vitro experiments confirmed that 2″‑O‑RhamnosylIcariside II-a compound derived from Epimedium-is the most effective among six potential active compounds. It promotes osteoblast differentiation, binds with HIF-1α, and inhibits both HIF-1α gene and protein expression, while enhancing COL1A1 protein expression under hypoxic conditions. In vivo experiments demonstrated its ability to improve bone microstructures and reduce bone loss by decreasing bone marrow adipose tissue, enhancing bone formation, and suppressing HIF-1α protein expression . This is the first study to describe the therapeutic effects of 2-O-RhamnosylIcariside II on osteoporosis through a mechanism targeting and inhibiting HIF-1α, providing new evidence supporting HIF-1α as a therapeutic target for osteoporosis treatment .

MAPK Signaling Pathway Regulation

The mitogen-activated protein kinase (MAPK) signaling system plays a core regulatory role in the bone metabolism network. This system comprises parallel signaling axes including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK, whose phosphorylation participates in regulating RANKL-induced osteoclastogenesis and bone resorption. MAPK-specific inhibitors can effectively block RANKL-mediated osteoclast differentiation .

Research on icariin has demonstrated its dual regulatory effects on the MAPK pathway depending on cell type and context. In LPS-induced osteoclast models, icariin inhibits LPS-induced bone resorption and the expression of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), while suppressing LPS-mediated activation of p38 and JNK. On osteoclasts, icariin suppresses LPS-mediated activation of the p38 and JNK pathways; on osteoblasts, it reduces LPS-induced activation of ERK1/2 and IκBα but increases p38 activation. Icariin inhibits LPS-induced osteoclastogenesis by suppressing activation of the p38 and JNK pathway, preventing inflammatory bone loss .

In rat bone marrow mesenchymal stem cell (BMSC) models, different concentrations of icariin significantly increase the phosphorylation of ERK and p38 kinases, and upregulate the downstream transcription factors Elk1 and c-Myc. The optimal concentration is 320 μg/L, indicating that icariin promotes BMSC proliferation by activating ERK and p38 MAPK signaling . Additionally, icariin suppresses osteogenic differentiation and promotes bone regeneration in periodontitis models by down-regulating the EphA2-RhoA signaling pathway, showing significant potential for treating periodontal bone loss .

BMP/Smad4 Signaling Pathway

The BMP/Smad4 signaling pathway is a key pathway leading to bone formation. Icariin modulates osteogenic differentiation through the BMP/Smad4 signaling pathway. Data demonstrate that 1 μM icariin increases the expression of BMP2, BMP4, Smad4, and p-Smad1/5/9. Notably, icariin upregulates alpha-enolase (Eno1) expression, and Eno1 might regulate osteogenic differentiation through the BMP/Smad4 signaling pathway, suggesting a potential connection between metabolic reprogramming and osteogenic differentiation .

Regulation of Bone Marrow Mesenchymal Stem Cells (BMSCs)

Icariin has shown significant potential in regulating BMSCs for osteoporosis treatment. It promotes BMSC differentiation toward osteoblasts while inhibiting adipocyte differentiation, and improves their migration and homing capabilities, thereby promoting bone formation and inhibiting bone loss .

Emerging Research: Plant-Derived Extracellular Nanovesicles

An emerging area of research involves Epimedium-derived extracellular nanovesicles (EELNs). These plant-derived vesicles exhibit typical exosome morphology with an average diameter of 130 nm and are rich in specific small-molecule metabolites and miRNAs. Network pharmacology and KEGG analysis highlight the therapeutic potential of EELNs in osteoporosis through multiple classical osteogenic pathways. In vitro experiments proved that EELNs potentiate the osteogenic differentiation of BMSCs by targeting the Pi3k/Akt/mTOR pathway. In vivo, EELN-loaded hydroxyapatite nano-whisker composites have been used to repair mandibular defects in osteoporosis rat models, indicating promising therapeutic applications for bone regeneration and mass maintenance .

Multi-Target Effects of Epimedium Flavonoids

Beyond the pathways discussed above, Epimedium flavonoids exert their anti-osteoporotic effects through multiple additional mechanisms, including :

Promoting bone formation: Through Notch, Hippo, and Wnt/β-catenin signaling pathways

Inhibiting bone resorption: By suppressing osteoclast differentiation and activity

Improving inflammatory response: Reducing pro-inflammatory cytokines like IL-6 and TNF-α

Anti-oxidative stress: Protecting bone cells from oxidative damage

Epimedium contains over 260 chemical compounds, primarily flavonoids, polysaccharides, lignans, and alkaloids, with 23 compounds identified as active against osteoporotic fractures. Among these, icariin, quercetin, and icariside II are the most important .

Study Design and Patient Population

A systematic review and meta-analysis published in Frontiers in Medicine evaluated 10 RCTs involving 890 patients with primary osteoporosis. The study adhered to PRISMA guidelines and searched multiple databases including PubMed, Embase, Cochrane Library, and Chinese medical databases. The analysis compared Epimedium-treated groups against control groups receiving conventional treatments, calcium and vitamin D supplements, or placebo.

Overall Efficacy Rate

The Epimedium group demonstrated a significantly higher overall response rate compared to controls, with an odds ratio of 3.80 (95% CI: 2.27–6.37; p < 0.0001). This finding indicates that patients receiving Epimedium extract were nearly four times more likely to achieve clinical efficacy than those receiving conventional treatment alone.

Bone Mineral Density Improvements Across Key Sites

The meta-analysis documented substantial improvements in BMD across multiple anatomical sites:

These effect sizes exceeding 1.0 indicate large clinical significance. Given that a one-standard-deviation decrease in BMD can increase fracture risk by 2.6 to 5.8 times, these improvements translate to meaningful reductions in fracture risk for patients with primary osteoporosis.

Bone Metabolism Marker Improvements

The analysis revealed Epimedium's bidirectional regulatory effects on bone metabolism:

Serum alkaline phosphatase (ALP) , a marker of bone resorption, decreased significantly by 8.78 units (95% CI: -12.80 to -4.77; p < 0.0001)

Bone-specific alkaline phosphatase (BALP) , indicating osteoblast activity, increased significantly by 6.73 units (95% CI: 3.32–10.14; p = 0.0001)

This pattern demonstrates Epimedium extract's ability to simultaneously inhibit bone resorption while promoting bone formation, addressing the fundamental pathophysiological imbalance underlying osteoporosis.

Rapid Lower Back Pain Relief

Beyond BMD improvements, Epimedium demonstrated significant efficacy in alleviating osteoporosis-related symptoms. Patients in the treatment group experienced notably faster relief from lower back pain, with an average reduction of 11.38 units (95% CI: -12.63 to -10.12;

p < 0.00001) compared to controls. This rapid symptomatic improvement is particularly valuable for patient quality of life and functional capacity.

Quality of Life and Functional Outcomes

The Epimedium treatment group also showed improvements in overall clinical symptoms and signs, with moderate-strength evidence supporting short-term efficacy in pain reduction and quality of life enhancement. These findings underscore Epimedium's potential as a comprehensive therapeutic intervention for primary osteoporosis, addressing both the structural and symptomatic aspects of the disease.

Comparison with Conventional Therapies

When compared to other Chinese patent medicines and calcium/vitamin D supplements, Epimedium total flavonoids treatment demonstrated comparable efficacy, positioning it as a reliable alternative option for primary osteoporosis. Notably, Epimedium capsules (EF capsule) have already been approved for clinical use by China's National Medical Products Administration (NMPA), confirming their established role in osteoporosis management.

Safety Findings from the Meta-Analysis

The safety analysis revealed encouraging results. Among the 10 RCTs included in the meta-analysis, adverse reactions were low, primarily consisting of mild gastrointestinal reactions or skin allergies. One study monitoring liver and kidney function over eight weeks found temporary enzyme elevations that returned to normal without clinical consequences.

Importantly, no severe hepatotoxicity, cardiovascular events, or other serious complications commonly associated with conventional osteoporosis treatments (such as atypical femoral fractures or osteonecrosis of the jaw) were observed with Epimedium therapy.

Tolerability and Patient Adherence

The favorable safety profile translates to better patient tolerability and adherence-a critical consideration in chronic conditions requiring long-term management. This makes Epimedium extract powder an attractive option for both clinical and nutraceutical applications, particularly for patients who may be intolerant to conventional pharmacotherapies or who seek natural alternatives.

Standardization: The Key to Consistent Efficacy

The clinical evidence supporting Epimedium for primary osteoporosis is compelling, but efficacy depends on consistent product quality. B2B buyers should prioritize the following factors:

HPLC verification, not UV testing: Icariin content must be verified by HPLC (High-Performance Liquid Chromatography) rather than UV methods. UV testing often overestimates flavonoid content, leading to inconsistent potency across batches. Products labeled as "10% icariin" can vary significantly if different testing methods are used.

Standardized icariin content: Clinical studies demonstrating efficacy utilized standardized Epimedium extracts with verified icariin content. Our Epimedium extract powder offers ≥10% icariin (HPLC-verified), ensuring consistent bioactivity batch after batch.

Water-soluble formulation: Traditional Epimedium extracts often show poor dispersion in water, sedimentation in beverages, and instability in liquid systems. Our water-soluble formulation forms a stable suspension, suitable for beverages, gummies, capsules, and powder blends.

Application Opportunities Across Product Categories

The robust clinical evidence for Epimedium in primary osteoporosis management presents significant opportunities across multiple product categories:

Dietary supplements – Bone health capsules, vitality support formulations, herbal wellness blends

Functional beverages – Bone health tonics, herbal infusions, powdered drink mixes

Functional foods – Bone-fortifying bars, nutritional snacks, fortified cereals

Medical nutrition – Clinical nutrition formulas for elderly or post-surgical recovery

The meta-analysis of 890 patients provides compelling evidence that Epimedium extract significantly improves bone mineral density, relieves lower back pain, and offers a favorable safety profile in primary osteoporosis patients . With a nearly fourfold increase in overall response rate compared to controls, Epimedium represents a scientifically validated, plant-based alternative to conventional pharmacotherapies.

From a mechanistic perspective, icariin and other Epimedium flavonoids exert their therapeutic effects through a sophisticated network of signaling pathways:

PI3K/Akt/GSK3β/β‑catenin integrated signaling

HIF‑1α targeting and inhibition

MAPK pathway regulation (p38, JNK, ERK)

BMP/Smad4 pathway activation

BMSC regulation promoting osteoblast differentiation

EphA2-RhoA pathway down-regulation

Emerging research on Epimedium-derived extracellular nanovesicles (EELNs) targeting the Pi3k/Akt/mTOR pathway further expands the therapeutic potential of this remarkable herb .

For B2B partners in the dietary supplement, functional food, and nutraceutical industries, Epimedium extract powder offers a unique opportunity to develop evidence-based bone health products that meet growing consumer demand for natural, clinically supported wellness ingredients. Our ≥10% icariin content (HPLC-verified) and water-soluble formulation ensure consistent potency and formulation versatility-empowering you to create products that deliver measurable results.

Contact us today to request your free sample, discuss formulation goals, or receive a customized quote for bulk Epimedium extract powder.

📩 Email: info@watersolu.com
📱 WhatsApp: +86 17396654828,